Alnylam Pharma To Receive $25 Mln Payment From Regeneron On FDA Approval Of Livsayis

Alnylam Pharma (ALNY) announced FDA approval of Livsayis for treating generalized myasthenia gravis. The company will receive a $25 million payment from Regeneron and is eligible for royalties. Alnylam shares rose 0.76% in pre-market trading.

Original reporting
Published Nov 19, 2026, 12:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefRegulation
Primary signal
$ALNY
Bullish
high confidence
Mentioned
$ALNY
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$ALNYBullishMed
01

Why it matters

The FDA approval triggers a contractual $25 million payment to Alnylam and establishes a potential royalty stream up to 15% on global net sales, improving the probability-weighted cash flow outlook.

02

Market read

A same-day FDA approval with explicit milestone and royalty terms is a tradable catalyst for ALNY, consistent with the reported pre-market uptick.

03

What to watch

Royalty upside depends on uptake in the anti-AChR antibody-positive generalized myasthenia gravis segment and competitive dynamics; the article does not provide sales forecasts or timeline for commercialization.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

Livsayis was discovered by Alnylam, advanced into Phase 2 by Alnylam, and later moved into an RNAi collaboration where Regeneron took over development, manufacturing, and commercialization.

Company-level read

Ticker impact

$ALNYBullishHigh confidence
Context

Alnylam says the FDA approved Livsayis for generalized myasthenia gravis and that it will receive a $25 million approval payment plus up to 15% royalties.

Expected impact

Likely upward pressure as traders price in the approval milestone and potential royalty stream from global net sales.

Evidence & confidence

The article is a direct, company-specific regulatory approval with concrete financial terms (approval payment and royalty rate cap), which typically drives immediate biotech sentiment and expectations for future cash flows.

Market effects

Reinforces RNAi platform validation and may modestly improve sentiment toward RNAi-focused biotech peers.

Primarily US biotech sentiment via Nasdaq-listed ALNY reaction.

US FDA approval can influence global commercialization expectations and partner royalty economics.

Counterpoint

The $25 million milestone is relatively small versus broader revenue expectations, so the stock reaction may fade if investors focus on longer-term sales ramp uncertainty.

Key entities

  • Alnylam Pharmaceuticals

    US-listed RNAi therapeutics company receiving an FDA approval milestone and royalties tied to Livsayis.

  • Regeneron

    Partner that assumed sole responsibility for Livsayis development, manufacturing, and commercialization.

  • Livsayis

    FDA-approved treatment for generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody-positive.

  • FDA

    Regulatory body that approved Livsayis, triggering milestone and royalty terms.

Related articles

$ALNYHighAI 8/10

Why Alnylam Pharmaceuticals (ALNY) Stock Is Up Today

Alnylam Pharmaceuticals (ALNY) stock rose 6.9% after the company shared positive long-term data for AMVUTTRA, reinforcing its cardiovascular benefits. The company also reiterated 2026 guidance and authorized a $1 billion share repurchase program, signaling confidence. Insider and institutional trading activity was noted, with mixed positions.

$ALNYMedAI 9/10

Alnylam's AMVUTTRA Shows Sustained Benefits Through Five Years In ATTR-CM

Alnylam Pharmaceuticals (ALNY) reported five-year data from the HELIOS-B study, showing that early treatment with AMVUTTRA (vutrisiran) in ATTR-CM patients led to better long-term outcomes, including a 48% reduction in mortality and cardiovascular events in the monotherapy group. The study also showed improved quality of life and stability in cardiac biomarkers. The safety profile remained consistent. The findings were presented at the American Heart Association Scientific Sessions 2026.